Watch GLUE. Know when insiders buy.
One email the day a filing lands. Free.
GLUE
Monte Rosa Therapeutics, Inc.
11.13
−0.23 −2.02%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
41
WATCH · shorts 41
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $949.5MP/E —DIV YIELD —FCF YIELD -3.38%REV TTM —NET INCOME −$161.1M −766.5%NET CASH —52W 9.35 – 25.31SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$49.1M | −$43.4M | — | — | −$44.1M | $4.7M | −$48.8M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$50M | −$44.5M | −194.9% | — | −$37.4M | $1.9M | −$39.2M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$49.7M | −$46.1M | −443.1% | — | −$43M | $767K | −$43.8M | Aug 6 |
| Q3 2025 · Sep 30 | — | — | — | −$33M | −$27.1M | — | — | $100.4M | $651K | $99.8M | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$15.6M | −$12.3M | — | — | −$34.7M | $1.7M | −$36.4M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | $44M | $46.9M | — | — | −$45.5M | $1.6M | −$47.1M | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | $13M | $13.4M | — | — | $128.9M | $183K | $128.7M | Mar 17 |
| Q3 2024 · Sep 30 | — | — | — | −$26.5M | −$23.9M | — | — | −$21M | $399K | −$21.4M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$32.6M | −$30.3M | — | — | −$27.8M | $2M | −$29.8M | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$34.9M | −$32M | — | — | −$38.2M | $1.4M | −$39.5M | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$34.9M | −$33.3M | — | — | $29.6M | $1.7M | $27.9M | Mar 20 |
| Q3 2023 · Sep 30 | — | — | — | −$37M | −$34.9M | — | — | −$24.7M | $1.7M | −$26.4M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$54.2M | −$38.6M | — | — | −$22.8M | $4.7M | −$27.5M | — | $0 |
| FY2024 · to Dec 31 | — | — | −$81.1M | −$72.7M | — | — | $42M | $4M | $38M | — | $0 |
| FY2023 · to Dec 31 | — | — | −$143.3M | −$135.4M | — | — | −$43.8M | $19M | −$62.8M | — | $0 |
| FY2022 · to Dec 31 | — | — | −$112.4M | −$108.5M | — | — | −$92.5M | $12.9M | −$105.4M | — | $0 |
| FY2021 · to Dec 31 | — | — | −$72.9M | −$74M | — | -2.96 | −$59.4M | $9.7M | −$69.1M | — | $0 |
| FY2020 · to Dec 31 | — | — | −$28M | −$35.9M | — | -23.65 | −$23.1M | $3.4M | −$26.4M | — | — |
Every number comes from Monte Rosa Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.